Document is current
Any future updates will be listed below
-
Authors
Pietschner, R.
Kolwelter, J.
Bosch, A.
Striepe, K.
Jung, S.
Kannenkeril, D.
Ott, C.
Schiffer, M.
Achenbach, S.
Schmieder, R. E. http://orcid.org/0000-0003-2356-5883
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03128528 at ClinicalTrials.govDocuments that mention this clinical trial
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
https://doi.org/10.1186/s12933-021-01410-7
The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial
https://doi.org/10.1007/s00392-022-02119-7
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
Universitätsklinikum Erlangen
- License Information
-
More Information
Article History
Received: 8 August 2021
Accepted: 27 October 2021
First Online: 9 November 2021
Declarations
:
: Written informed consent was obtained from each patient before study inclusion. The study protocol of each trial was approved by the Local Ethics Committee (University of Erlangen-Nuremberg), and the studies were conducted in accordance with the Declaration of Helsinki and the principles of good clinical practice guidelines.
: All authors gave full consent for publication.
: All authors declare that they have no competing interests.
